Novavax, Inc. (NASDAQ:NVAX) RSI Points to Oversold

Cornelia Mascio
Aprile 20, 2017

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. They now have a United States dollars 12 price target on the stock. The stock was trading on below-average volume.

U.S. based company, Novavax, Inc. Piermont Capital Management Inc. increased its position in Novavax by 9.2% in the third quarter. (NVAX) to Neutral by settling a price target of $1.5 on 9/20/16.

Price to Sale ratio of WDR stands at 1.16 while Price to Book Ratio stands at 1.68. Citigroup Downgrades the company's stock to Neutral on 9/16/16 by setting a price target of $1.5.

02/28/2017 - Novavax, Inc. had its " rating reiterated by analysts at Ladenburg Thalmann.

Novavax, Inc. (NVAX) now has a consensus Price Target of $3.7. The stock touched 52-week High of $21.34 on 04/22/16 and 52-week Low of $14.28 on 11/01/16. Sell-side firms now have a consensus recommendation of 2.60 on the shares. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

Novavax, Inc.'s RSI is 19.57. Analysts expect that Novavax will post ($0.62) earnings per share for the current year. The analysts offering Earnings Estimates for the company were believing that Novavax, Inc. The difference between Actual EPS and Estimated EPS was 0.02 Percent. The firm's revenue for the quarter was down 7.7% compared to the same quarter previous year. (NASDAQ:NVAX) have received a consensus recommendation of "Hold" from the twelve ratings firms that are now covering the company. A total of 6.09 million shares exchanged at hands and its average trading volume is standing at 6.22 million shares. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.02.

NVAX has a 1-year high price of $ 8.49 and 1-year low price of $0.73.

Stock is now moving with a negative distance from the 200 day simple moving average of approximately -72.48%, and has a poor year to date (YTD) performance of -34.39% which means the stock is constantly subtracting to its value from the previous fiscal year end price. The average numbers of shares are traded in a security per day, during the recent 3-month period. The company has a Return on Assets (ROA) of -56.80%. The return on equity ratio or ROE stands at -329.6 percent while most common profitability ratio return on investment (ROI) was 0 percent.

While looking at the Stock's Performance, Novavax, Inc. now shows a Weekly Performance of 0.22%, where Monthly Performance is -35.11%, Quarterly performance is -37.79%, 6 Months performance is -44.32% and yearly performance percentage is -83.81%. Inside the closing six months period the stock's performance declined -46.83% while overall yearly performance lost -84.89%. Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. According to these analysts, the Low Revenue Estimate for Novavax, 4 Million and the High Revenue Estimate is 9 Million. The Stock opened today's session at $0.88 and now the price is hovering at $0.83 by showing decrease of -5.48 percent. Its Price to Cash Flow ratio shows the value of 8.64, whereas, the industry and sector ratio of Price to Cash Flow ticked at 85.2 and 14.68 respectively.

According to Finviz reported data, The SMA20 of the stock is at -25.87 percent, SMA50 is -36.36 percent, while SMA200 is -72.68 percent.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE